Nucleic Acids Research, 1995, Vol. 23, No. 14 2661-2668
© 1995
CHEMISTRY |
Synthesis of oligodeoxyribonucleotide N3'
P5' phosphoramidates
Lynx Therpeutics Inc. 3832 bay Center Place, Hayward, CA 94545, USA
*To whom correspondence should be addressed
Received April 7, 1995. Accepted May 30, 1995.
An efficient synthesis of the novel nucleic acid analogs oligodeoxyribonucleotide N3'
P5' phosphoramidates, where the 3'-oxygen is substituted by a 3'-nitrogen, is described. Synthesis of the title compounds was accomplished by the following synthetic steps. First, 5O-DMT base-protected-3'-amino-2',3'-dkieoxynucleosides were prepared. The 3'-aminopyrimldlnes were obtained via the corresponding 2',3'-anhydronucleosides, whereas 3'-amlnopurines were derived via 2'-deoxyxylo precursors. Second, using the prepared 3'-aminonucleosides, oligonucleotide N3'
P5' phosphoramidates were synthesized on a solid support. Oligonucleotide chain assembly was based upon a carbon tetrachloride-driven oxidatlve coupling of the appropriately protected 3'-amlnonucleosides with the 5'-H-phosphonate diester group, resulting in the formation of an intemucleoside phosphoramldate link. Fully deprotected oligonucleotide N3'
P5' phosphoramidates were characterized by ion exchange and reversed phase HPLC, capillary and slab gel etectrophoresis and by 31P NMR analysis. Oligonucleotide N3'
P5' phosphoramidates form remarkably stable duplexes with complementary RNA strands and also with themselves, where the melting temperature of the complexes exceeded that for the parent phosphodiester compounds by 2633°C. Additionally, duplexes formed by oligonucleo ide phosphoramidates with singlestranded DNA were also more thermally stable than those formed by phosphodiesters. The described properties indicate that these compounds may have great potential in oligonucleotide-based diagnostics and therapeutic applications.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
N. Dias and C. A. Stein Antisense Oligonucleotides: Basic Concepts and Mechanisms Mol. Cancer Ther., March 1, 2002; 1(5): 347 - 355. [Full Text] [PDF] |
||||
![]() |
A. M. Gewirtz, D. L. Sokol, and M. Z. Ratajczak Nucleic Acid Therapeutics: State of the Art and Future Prospects Blood, August 1, 1998; 92(3): 712 - 736. [Full Text] [PDF] |
||||
![]() |
T. Skorski, D. Perrotti, M. Nieborowska-Skorska, S. Gryaznov, and B. Calabretta Antileukemia effect of c-myc N3'right-arrowP5' phosphoramidate antisense oligonucleotides in vivo PNAS, April 15, 1997; 94(8): 3966 - 3971. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Giovannangeli, S. Diviacco, V. Labrousse, S. Gryaznov, P. Charneau, and C. Helene Accessibility of nuclear DNA to triplex-forming oligonucleotides: The integrated HIV-1 provirus as a target PNAS, January 7, 1997; 94(1): 79 - 84. [Abstract] [Full Text] [PDF] |
||||
![]() |
F.-X. Barre, S. Ait-Si-Ali, C. Giovannangeli, R. Luis, P. Robin, L. L. Pritchard, C. Helene, and A. Harel-Bellan Unambiguous demonstration of triple-helix-directed gene modification PNAS, March 28, 2000; 97(7): 3084 - 3088. [Abstract] [Full Text] [PDF] |
||||


